Myris Therapeutics
  • HOME
  • COMPANY
    • ABOUT
    • OUR TEAM
    • SCIENTIFIC PUBLICATIONS
  • NEWS
  • CONTACT
Select Page
Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer

Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer

by Laura Benjamin | Feb 20, 2025 | News

Myris Therapeutics emerges from stealth to announce new name and strategic focus Proprietary polymer chemistry enables ultra-high drug to antibody ratios of 50 – 100 and new chemical space for precision targeted ADC payloads PITTSBURGH, Feb. 20,...

Recent Posts

  • Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
  • BioHybrid Solutions Holdings, Inc. Announces Expansion of its Drug Development Leadership  
  • BioHybrid Solutions Holdings, Inc. Appoints Mark Murcko as Board Member
  • BioHybrid Solutions™ announces the formation of its Holdings Corporation and Subsidiaries
  • BioHybrid Solutions™ Announces Jean Pineault as President and Chief Executive Officer

Recent Comments

    Archives

    • February 2025
    • June 2023
    • September 2022
    • May 2022
    • January 2022
    • December 2019
    • November 2019
    • April 2017
    • November 2016
    • October 2016
    Copyright © Myris Therapeutics